<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99476</identifier>
<setSpec>0004-2927</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Theragnosis: a new concept in cancer treatment</dc:title>
<dc:description xml:lang="en">The introduction of nanotechnology into pharmacology (&#147;nanomedicine&#148;) has revolutionized the drug delivery field, allowing the appearance of new treatments with improved efficacy. These nanodevices can be exploited for anticancer therapy as a means to administer the drug and/or gene into the body in a controlled manner, and to deliver it to the tumor. In this investigation we analyze the real possibilities in the development of nanotechnologies which combine sufficient drug loading, targeted anticancer activity, and imaging capabilities (i.e., &#147;nanotheragnostics&#148;). In recent years, much attention has been paid to the development of iron oxide core-based nanoparticles for drug/gene delivery applications [3], taking advantage of the unique ability of magnetic particles to be guided by a magnetic gradient. There are not many reports in the literature concerning the development of multifunctional drug delivery systems with both magnetic responsiveness and diagnostic imaging capabilities. Surprisingly, these studies were focused on the investigation of diagnostic and therapeutic functions independently, and, moreover, were performed in vitro, with no clear-cut in-vivo proof of concept of combined imaging and therapeutic activity. It is certain that extensive in-vivo investigations are essential to definitively demonstrate the promise of &#147;nanotheragnostic&#148; as a cutting edge multifunctional platform in cancer therapy(AU)</dc:description>
<dc:creator>Gallardo, V</dc:creator>
<dc:creator>Sáez-Fernández, E</dc:creator>
<dc:creator>Pérez-Artacho, B</dc:creator>
<dc:creator>Martínez-Soler, G. I</dc:creator>
<dc:creator>Arias, J. L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El desarrollo de sistemas coloidales constituidos por un núcleo de óxido de hierro ha generado un importante interés en el transporte de fármacos y genes. Esto es debido a la capacidad de estos nanosistemas de ser guiados por gradientes magnéticos internos o externos hasta el lugar de acción. Cuando este núcleo magnético está constituido por nanopartículas de óxido de hierro ultra pequeñas(diámetro &lt; 20 nm), el coloide compuesto adquiere la capacidad de ser utilizado como agente de contraste en resonancia magnética de imagen (RMI). Este revolucionario concepto de agente teragnóstico (terapia + diagnóstico) se postula como sumamente eficaz en el tratamiento y diagnóstico simultáneo de patologías de elevada morbi-mortalidad como el cáncer. Pretendemos así determinar las posibilidades reales de desarrollar nanoplataformas que combinen la vehiculización adecuada de fármacos, una actividad antitumoral eficiente y una utilidad clara como agentes de contraste en RMI. La casi totalidad de los estudios de desarrollo de estos nanosistemas han sido realizados in vitro. De esta manera, para demostrar las posibilidades tan prometedoras que ofrece la nanoteragnosis in vivo son necesarias profundas investigaciones sobre estas nanoplataformas funcionales(AU)</dc:description>
<dc:source>Ars pharm;51(supl.3): 177-181, jul. 2010.</dc:source>
<dc:identifier>ibc-99476</dc:identifier>
<dc:title xml:lang="es">Teragnosis: un nuevo concepto en el tratamiento del cáncer</dc:title>
<dc:subject>^d52498</dc:subject>
<dc:subject>^d29564^s22048</dc:subject>
<dc:subject>^d29564^s22049</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29564^s22066</dc:subject>
<dc:subject>^d29564^s22045</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d14523^s22078</dc:subject>
<dc:subject>^d14523^s22079</dc:subject>
<dc:subject>^d52498^s22074</dc:subject>
<dc:subject>^d52498^s22000</dc:subject>
<dc:subject>^d9562^s22067</dc:subject>
<dc:subject>^d974^s22078</dc:subject>
<dc:subject>^d974^s22079</dc:subject>
<dc:subject>^d52498^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201007</dc:date>
</metadata>
</record>
</ibecs-document>
